Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 19, 2005Arthritis Research & TherapyOpen Access

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

View Full Paper
Ask AI
Bookmark
Share

Authors

XBXenofon BaraliakosRheumazentrum RuhrgebietJLJoachim ListingUniversity of CopenhagenJBJ. BrandtUniversity Hospital Heidelberg

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Baraliakos et al. (2005) studied this question.

synapsesocial.com/papers/6a7fe1b1e507fb29f6960348https://doi.org/10.1186/ar1693
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years2005 · 183 citations
  2. 2Long‐term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three‐month, randomized, placebo‐controlled trial2003 · 265 citations
  3. 3Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy1998 · 367 citations
  4. 4Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease2003 · 2,028 citations